Zai Lab hires ex-Lilly CFO who departed after investigation found 'inappropriate' behavior Biogen takes full control of troubled Aduhelm in revamped Eisai deal HIMSS22: Google Health announces Meditech as the first EHR vendor to integrate with Care Studio FDA slaps LuSys Labs with Class I label for recall of antibody, antigen COVID tests Passage Bio chips away at workforce, prioritizes R&D with UPenn's James Wilson Amazon hires Providence's Aaron Martin as tech giant bulks up its healthcare leadership BioIntelliSense debuts rechargeable version of its wearable vital sign tracker In rare flop, Merck calls it quits on Keytruda-Lynparza combo in prostate cancer We have achieved peak biotech formation. It's time for 'musical chairs' Top Pfizer, Moderna execs at odds on need for 4th COVID-19 vaccine dose SXSW 2022: The business case for investing in innovating health equity Element Biosciences unveils Aviti benchtop sequencing system Federal jury sides with Sutter Health in antitrust case surrounding health plans GE Healthcare rolls out digital tool subscriptions for its hand-held ultrasound system Ovid finds new focus in epilepsy, but trims staff to extend cash runway Featured Story | By Kyle LaHucik Zai Lab has hired ex-Eli Lilly finance chief Josh Smiley, who exited the Big Pharma last year after an external investigation found he had "poor judgment" and exhibited "inappropriate" behavior with multiple coworkers. read more |
| |
|---|
|
Top Stories By Angus Liu Even before a highly anticipated coverage decision, Eisai has decided to abandon Aduhelm amid a dismal commercial outlook, bowing out of the marketing of the controversial Alzheimer’s disease drug that it co-developed with Biogen. read more By Dave Muoio The "early stages" collaboration represents another avenue for Google Health to get its pre-commercial clinical software in front of practicing clinicians. read more By Andrea Park The Class I recall covers LuSys Laboratories’ antigen test kits for both saliva and nasal samples, as well as the blood-based antibody test. read more By Max Bayer Passage Bio is doubling down on a partnership with James Wilson, M.D., Ph.D, and his University of Pennsylvania lab even as the gene therapy biotech plans to trim its workforce 13% in the latest of a string of setbacks. read more By Heather Landi Providence executive Aaron Martin is returning to Amazon to deepen the company's partnerships with medical providers. It marks the latest hire by the online retail giant, which has been quietly building a deep bench of healthcare talent. read more By Andrea Park Aiming to capture some of the “fix it and forget it” mystique of so many of the world’s great household devices, BioIntelliSense has unveiled yet another iteration of its wearable technology for passive, continuous health data collection. read more By Angus Liu The combination of two powerful drugs with excellent clinical track records isn’t necessarily a guarantee for success. Merck just found out that a pairing of Keytruda and Lynparza didn't work in some prostate cancer patients. read more By Annalee Armstrong For patients, there’s never been a better time for medical innovation. But how many biotechs is too many? read more By Fraiser Kansteiner Top executives at pandemic juggernauts Pfizer and Moderna are at odds on the need for a fourth COVID-19 vaccine dose. One says a second booster is needed “right now,” while the other thinks a fourth mRNA shot may only be essential for older adults and the immunocompromised. read more By Paige Minemyer AUSTIN, Texas—As the healthcare industry grapples with equity challenges, experts are laying out the business case for investors to back new innovations in this space. read more By Conor Hale After raising $276 million in venture capital last year, Element Biosciences’ first DNA sequencing product is making its public debut. read more By Robert King A federal jury sided with Northern California hospital system Sutter Health over a lawsuit surrounding allegations it stifled competition via all or none contracts with insurers. read more By Andrea Park Last year, GE Healthcare upgraded its decade-old line of portable ultrasound devices with the launch of the Vscan Air, a wireless, pocket-sized system for whole-body scanning. Almost exactly one year later, the Vscan Air is getting an upgrade of its own. read more By Max Bayer Ovid Therapeutics seems to have found its focus after a rough year: epilepsy. But the biotech will move towards this new direction with 20% fewer people at the company. read more | 